Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | NAMPT | P43490 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1499493 | 0.95 | NPC1 (0.62) | HPGDNPC1RAB9ANAMPTSMN1; SMN2 | |
| SCHEMBL10099546 | 0.93 | HPGD (0.69) | HPGDNPC1RAB9ANAMPTSMN1; SMN2 | |
| SCHEMBL1499289 | 0.89 | KCNK9 (0.59) | HPGDNPC1RAB9ANAMPTSMN1; SMN2 | |
| SCHEMBL29973699 | 0.89 | KCNK9 (0.59) | HPGDNPC1RAB9ANAMPTSMN1; SMN2 | |
| SCHEMBL1499500 | 0.87 | MTNR1B (0.57) | HPGDNPC1RAB9ANAMPTSMN1; SMN2 | |
| SCHEMBL1499587 | 0.87 | NAMPT (0.58) | HPGDNPC1RAB9ANAMPTSMN1; SMN2 | |
| SCHEMBL1499303 | 0.85 | NAMPT (0.54) | HPGDNPC1RAB9ANAMPTSMN1; SMN2 | |
| SCHEMBL12767159 | 0.85 | SNCA (0.56) | HPGDNPC1RAB9ANAMPTSMN1; SMN2 | |
| SCHEMBL12966949 | 0.84 | MCHR1 (0.56) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1499593 | 0.83 | KCNK9 (0.61) | NPC1RAB9ANAMPTSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10130595-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2018-11-20 | — | — | US | claimed |
| US-20160166519-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CT NATIONALE DE RECH SCIENT (FR) | 2016-06-16 | — | — | US | claimed |
| US-9233931-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2016-01-12 | — | — | US | claimed |
| US-20140155436-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (FR) | 2014-06-05 | — | — | US | claimed |
| JP-2011509280-A | — | — | 2011-03-24 | — | — | JP | claimed |
| US-20110053975-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2011-03-03 | — | — | US | claimed |
| EP-2235000-A2 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | Centre National de la Recherche Scientifique (CNRS) (FR) | 2010-10-06 | — | — | EP | claimed |
| WO-2009087238-A9 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-02-25 | — | — | WO | claimed |
| WO-2009087238-A2 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2009-07-16 | — | — | WO | claimed |
| EP-3536691-B1 | CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NAT RECH SCIENT (FR) | 2022-10-05 | — | — | EP | disclosed |
| EP-2235000-B1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NAT RECH SCIENT (FR) | 2020-06-17 | — | — | EP | disclosed |
| EP-2235000-B1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NAT RECH SCIENT (FR) | 2020-06-17 | — | — | EP | disclosed |
| US-10654813-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-05-19 | — | — | US | disclosed |
| US-10654813-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-05-19 | — | — | US | disclosed |
| US-20110053975-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2011-03-03 | — | — | US | disclosed |
| US-20110053975-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2011-03-03 | — | — | US | disclosed |
| US-20110053975-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2011-03-03 | — | — | US | disclosed |
| EP-2235000-A2 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | Centre National de la Recherche Scientifique (CNRS) (FR) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009087238-A9 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-02-25 | — | — | WO | disclosed |
| WO-2009087238-A2 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10130595-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | RBM17, RBM22, SF3B1 | HPGD 1547/4885NPC1 769/4885RAB9A 3266/4885 |
| US-20160166519-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | RBM17, RBM22, SF3B1 | HPGD 1547/4885NPC1 769/4885RAB9A 3266/4885 |
| US-10654813-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | RBM17, RBM22, PRPF40A | HPGD 1902/4885NPC1 589/4885RAB9A 3640/4885 |
| US-20140155436-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | RBM17, SF3B5, SF3B1 | HPGD 4291/4885NPC1 922/4885RAB9A 4085/4885 |
| US-20110053975-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | RBM17, SF3B5, SF3B1 | HPGD 4291/4885NPC1 922/4885RAB9A 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.